Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial

Clinical Lymphoma Myeloma and Leukemia（2024）

引用 0|浏览44

暂无评分

摘要

•Ven-cobi showed limited efficacy, similar to venetoclax alone, in R/R AML.•Ven-cobi had additional toxicity versus venetoclax alone in patients with R/R AML.•High MCL-1 levels and TP53/signaling mutations may promote ven-cobi resistance.•These findings may optimize future trials of BCL-2/MAPK inhibitor combinations.

查看译文

关键词

B-cell lymphoma-2,Biomarker,Mitogen-activated protein kinase pathway,Targeted therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要